{
    "nctId": "NCT02726477",
    "briefTitle": "Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema",
    "officialTitle": "Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Lymphedema",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "volume changes % measured by perometry",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women completed all primary and adjuvant treatments (surgery, chemotherapy, radiotherapy)\n* age 20-40 with unilateral BCRL, stage I or II, BMI of 18-25\n* Volume difference \u2265300 mL between the normal and lymphedematous upper extremity based on perometry evaluation\n* No evidence of breast cancer recurrence\n* At least 6 months postoperative from axillary lymph node dissection\n\nExclusion Criteria:\n\n* Bilateral lymphedema or stage III lymphedema\n* History of bilateral axillary lymph node dissection\n* Recent history of cellulitis in the affected extremity (within last 3 months)\n* Recurrent breast cancer or other malignancy\n* Current (within last month) use of chemotherapy for breast or other malignancy\n* Current (within last 3 months) use of radiation for breast or other malignancy\n* Recent (within last month) or current intensive MLD and/or short stretch bandage use\n* Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months)\n* Pregnant or nursing (lactating) women\n* Patients that take drugs like diosmin at the time of enrollment, or within 30 days.\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.\n* Unable to comply with the protocol, measurement and follow-up schedule.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT"
}